FDA Approves Afrezza for Children: A New Needle-Free Mealtime Insulin Option

For families managing type 1 diabetes, every meal, snack, birthday party, and school lunch often comes with another insulin injection. That routine may soon become much easier.

The U.S. Food and Drug Administration (FDA) has approved Afrezza®, an inhaled mealtime insulin, for children and adolescents ages 6 and older living with type 1 or type 2 diabetes. The approval makes Afrezza the first and only needle-free mealtime insulin available for pediatric patients in the United States.

What Is Afrezza?

Afrezza is a rapid-acting insulin that is inhaled through a small handheld device instead of injected with a syringe, pen, or insulin pump. Once inhaled, the insulin is absorbed through the lungs and enters the bloodstream quickly.

Unlike many injectable mealtime insulins that are taken before eating, Afrezza can be taken at the beginning of a meal, providing more flexibility when kids have unpredictable appetites or eating schedules.

Why This Matters

Managing diabetes in children is challenging. Kids may not finish the meal they planned to eat, decide they want seconds, or suddenly head outside to play sports. Those everyday situations can make insulin dosing stressful for both children and parents.

An inhaled insulin offers several potential benefits:

• No mealtime injections

• Fast absorption that more closely mimics the body's natural insulin response

• More flexibility for school lunches, sports, and social activities

• A discreet option that may reduce anxiety around insulin dosing

For many families, reducing the number of daily needle sticks could significantly improve quality of life.

How Fast Does It Work?

Afrezza is considered an ultra rapid-acting insulin. It begins lowering blood sugar in approximately 12 minutes and leaves the body more quickly than many traditional rapid-acting injectable insulins.

This quick action can help better match the rise in blood sugar that occurs after eating while reducing the amount of insulin that remains active hours later.

Who Can Use It?

The FDA approval includes children and adolescents ages 6 and older with:

• Type 1 diabetes (used together with a long-acting basal insulin)

• Type 2 diabetes when mealtime insulin is needed

Afrezza is not a replacement for long-acting insulin in people with type 1 diabetes. It is designed specifically for mealtime blood sugar management.

Is It Right for Everyone?

No. Because Afrezza is inhaled through the lungs, it is not recommended for everyone.

People with asthma, chronic obstructive pulmonary disease (COPD), or certain other lung conditions should not use Afrezza because it can cause serious breathing problems. Healthcare providers also perform a lung function test before starting treatment and periodically afterward.

Afrezza is also not intended for treating diabetic ketoacidosis (DKA).

What Families Should Know

The approval was supported by the Phase 3 INHALE-1 clinical trial, which demonstrated that Afrezza provided blood sugar control comparable to traditional mealtime injections while offering children and families a needle-free alternative. Clinical experts believe this additional option may help reduce some of the daily burden of diabetes management.

As with any insulin therapy, families should work closely with their diabetes care team to determine whether Afrezza is appropriate and to learn proper dosing and monitoring.

The Bottom Line

There is no one-size-fits-all approach to diabetes care. Some children thrive using insulin pumps, others prefer injections, and now many families will have another choice.

For kids who struggle with multiple daily injections or want a more flexible mealtime option, the FDA's approval of Afrezza represents an exciting new step forward. While it won't replace every insulin regimen, it gives children and their healthcare providers another tool to help manage diabetes while making everyday life a little easier.

Direct Diabetes is committed to keeping our community informed about the latest advances in diabetes care so patients and families can make informed decisions with their healthcare providers.